MARKET MOVES

Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 target

2026-08-21·Economic Times·Impact 1/5 · Low

MeridStreet AI summary

Jefferies, a financial brokerage, has started providing analysis and investment advice on Anthem Biosciences, a biotechnology company. They have given the company a Buy rating, which means they think it's a good investment opportunity. The brokerage also set a target price of Rs 1,050 for the company's stock, suggesting that it could increase by around 20% in value.

Source reporting

Read the source report: Economic Times →

MeridStreet analysis

Why it matters

Jefferies has initiated coverage on Anthem Biosciences with a Buy rating and a target price, implying a potential upside. This could lead to increased investor interest and a rise in the company's stock price.

Market impact

Impact score

1 / 5

Market signal

Positive / risk-on

Transmission channels

Jefferies initiates coverage→Buy rating boosts sentiment→Investor interest increases→Stock price rises

Likely winners & losers

Winners

biotech stocks
Anthem Biosciences investors

Related coverage

$20 billion bet: Where is Warren Buffett's successor spending Berkshire's cash pile after 14 quarters? Economic Times · 2026-08-09
Berkshire Hathaway spends down cash pile under CEO Greg Abel Economic Times · 2026-08-09

Explore the intelligence

Live news feed

Real-time global markets, trade & geopolitics

All stories

Every tracked story cluster

Global macro

GDP, inflation & policy rates across major economies

Open the live MeridStreet terminal →

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to Economic Times. For information only — not financial advice.